Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | SLO | ENG

Naslov:Letno srečanje ASCO
Avtorji:Čufer, Tanja (Avtor)
Jezik:Slovenski jezik
Tipologija:1.04 - Strokovni članek
Organizacija:LogoOI - Onkološki inštitut Ljubljana
Ključne besede:klinična onkologija, imunoterapija, imunska zdravila, novosti
Leto izida:2015
UDK:616-006
ISSN pri članku:1408-1741
OceCobissID:65324032 Povezava se odpre v novem oknu
COBISS_ID:2139771 Povezava se odpre v novem oknu
Število ogledov:870
Število prenosov:32
Datoteke:.pdf RAZ_Cufer_Tanja_i2015.pdf (1,18 MB)
 
Nadgradivo:Onkologija
Onkološki inštitut
 
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
Licenca:Priznanje avtorstva Novo okno
:
  
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Sekundarni jezik

Jezik:Angleški jezik
Naslov:ASCO Annual Meeting
Povzetek:In the end of May this year, Chicago hosted the traditional annual meeting of oncologists from around the world, which was organised by the American Society of Clinical Oncology (ASCO). Once again, the meeting was attended by more than 30,000 oncologists and other scientists from all over the world. The main topic of this year’s ASCO meeting was definitely cancer immunotherapy. For many years, we have hoped to be able to destroy or at least control cancer cells by stimulating the organism’s own defence. There have been some ups but mostly many downs of immunotherapy. Interferons, interleukins and vaccines have shown a very small level of efficacy, and, even so, only in some types of cancer, alongside a disproportionally high toxicity. A breakthrough was achieved a few years ago, when new immuno-medicines, inhibitors of control switches in T lymphocytes (so-called checkpoint inhibitors), were introduced into clinical trials. In many types of cancer, these medicines led to remissions, which were, most importantly, long-term in patients with remission.

Arhiv

niGradiv

Nazaj